VJOncology is committed to improving our service to you

ESMO Breast 2020 | HER2CLIMB: tucatinib in combination w/ capecitabine & trastuzumab

VJOncology is committed to improving our service to you

Giuseppe Curigliano

Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, discusses the HER2CLIMB trial (NCT02614794) which investigated tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with advanced HER2+ breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter